ArticleBlood advances2026

Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL.

Jonathan D Paolino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.